Characterizing real world safety profile of oral Janus kinase inhibitors among adult atopic dermatitis patients: evidence transporting from the rheumatoid arthritis population-Reference-Cited by-同舟云学术

Characterizing real world safety profile of oral Janus kinase inhibitors among adult atopic dermatitis patients: evidence transporting from the rheumatoid arthritis population

Published:2022-06-28 Issue:8 Volume:38 Page:1431-1437
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Montez-Rath Maria E.¹,Lubwama Robert²,Kapphahn Kris³,Ling Albee Y.³,LoCasale Robert²,Robinson Lacey²,Chandross Karen J.²⁴,Desai Manisha³

Affiliation:

1. Department of Medicine, Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA, USA

2. Sanofi, Bridgewater, NJ, USA

3. Department of Medicine, Division of Biomedical Informatics Research, Quantitative Sciences Unit, Stanford University School of Medicine, Palo Alto, CA, USA

4. Sanofi, R&D, Bridgewater, NJ, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2022.2088715

Reference34 articles.

1. Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population

2. 204 A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (AD-QUEST): Baseline treatment patterns and unmet needs assessment

3. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data

5. AbbVie. European Commission Approves RINVOQ (upadacitinib) as First JAK inhibitor in the European Union for the treatment of both adults and adolescents with moderate to severe atopic dermatitis [Internet]; 2021 [cited 2021 Aug 24]. Available from: https://www.prnewswire.com/news-releases/european-commission-approves-rinvoq-upadacitinib-as-first-jak-inhibitor-in-the-european-union-for-the-treatment-of-both-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-301361058.html.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors;Dermatology and Therapy;2024-08-08

2. Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure;American Journal of Clinical Dermatology;2024-06-18

3. An Overview of Current Methods for Real-world Applications to Generalize or Transport Clinical Trial Findings to Target Populations of Interest;Epidemiology;2023-05-26

4. How to Understand Personalized Medicine in Atopic Dermatitis Nowadays?;International Journal of Molecular Sciences;2023-04-20

5. Glass-ceramics in dentistry: Fundamentals, technologies, experimental techniques, applications, and open issues;Progress in Materials Science;2023-02